14 recruiting, 10 not yet recruiting, 4 unknown, 1 active not recruiting. 21 Phase 2, 16 Phase 1, 5 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Lisaftoclax: new trials by email Literature Review of Lisaftoclax trials Research Report on Lisaftoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib - Richter Syndrome | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2026-09-01 | 2026-09-21 |
| Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Lisaftoclax Plus Azacitidine - Acute Myeloid Leukemia (AML), Maintenance Treatment | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 191 | 2026-08-10 | 2026-07-07 |
| A Single-center, Prospective, Exploratory Clinical Study Lisaftoclax - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | LanZhou University | 30 | 2026-08-01 | 2026-08-31 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma Lisaftoclax - Indolent Lymphoma, WM | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 75 | 2026-07-10 | 2026-07-29 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy Lisaftoclax, Pirtobrutinib - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 45 | 2026-06-30 | 2026-07-06 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma Lisaftoclax, Chidamide, rituximab - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-22 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL Pirtobrutinib, Lisaftoclax, Rituximab - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 29 | 2025-11-30 | 2025-12-01 |
| Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 25 | 2025-09-10 | 2026-07-28 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. APG-2575, Placebo - SLE | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-08-09 | 2025-12-16 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia APG-2575(Lisaftoclax ), Placebo, Azacitidine Injection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 486 | 2024-06-11 | 2025-11-25 |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine - CLL/SLL | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 344 | 2024-04-07 | 2026-07-28 |
| Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia Ivosidenib, Venetoclax, Gilteritinib - AML, Refractory | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 458 | 2024-02-22 | 2026-08-07 |
| APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors APG-115, APG-2575 - Neuroblastoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 100 | 2023-02-28 | 2026-08-21 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Myeloid, Acute (5) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (2) · Amyloidosis (1) · Breast Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia, Promyelocytic, Acute (1)
Ascentage Pharma Group Inc. (17) · Institute of Hematology & Blood Diseases Hospital, China (4) · Henan Cancer Hospital (2) · Sun Yat-sen University (2) · First Affiliated Hospital of Zhejiang University (1) · Guangdong Second Provincial General Hospital (1) · LanZhou University (1) · M.D. Anderson Cancer Center (1) · Peking University First Hospital (1) · Ruijin Hospital (1) · The Affiliated People's Hospital of Ningbo University (1) · The First Affiliated Hospital of Soochow University (1)
China (24) · United States (8) · Australia (5) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1)
Yifan Zhai, MD, PhD (5) · Yifan Zhai, M.D., Ph.D. (3) · Jie Jin, M.D. (2) · Guillermo Garcia-Manero, M.D. (1) · Guopan Yu, PhD (1) · Jianxiang Wang, M.D. (1) · Jianxiang Wang, MD (1) · Jianyong Li, M.D. (1) · Keshu Zhou, M.D., Ph.D. (1) · Lugui Qiu, M.D., Ph.D. (1) · Nicholas J Short, MD (1) · Qian Niu, MD (1) · Sheng Chen, Ph.D (1) · Xiaofan Zhu, MD (1) · Xiaojun Huang, M.D., Ph.D. (1)